---
title: "Stem Cell Therapy for Heart Failure: What the Research Shows and Who May Be a Candidate"
description: "An honest guide to mesenchymal stem cell (MSC) therapy for congestive heart failure: what the trials show (including negative ones), our 300 million cell IV protocol and price, heart-specific risks and flight limits, and who may be a candidate."
canonical: "https://dreambody.clinic/stem-cell-therapy-heart-failure-research/"
---

# Stem Cell Therapy for Heart Failure: What the Research Shows and Who May Be a Candidate

Maybe it started with a heart attack, or nobody ever found a clear cause. Now a number follows you to every appointment: your ejection fraction. You’re on several medicines, you get winded on the stairs, and you’re wondering whether anything else might help. This guide covers what happens in heart failure, what the research on mesenchymal stem cells (MSCs) shows, what our protocol involves and costs, and who may be a candidate.

We’ll be straightforward: MSC therapy for heart failure is investigational. Some trials reported encouraging signals, the largest trial missed its main goal, and nothing here replaces your cardiologist’s care.

## What Happens in Heart Failure

Heart failure means the heart can’t pump as well as your body needs, so fluid can build up and cause shortness of breath, fatigue and swelling.

Cardiologists describe it by **ejection fraction (EF)**, the share of blood the main pumping chamber pushes out with each beat (normal is roughly 50% to 70%). In **HFrEF** (reduced EF, 40% or less), the muscle is weakened or scarred, often after a heart attack. In **HFpEF** (preserved EF), the heart is stiff and doesn’t fill well. **Almost all MSC trials enrolled people with HFrEF**; there’s very little evidence for HFpEF.

## What Standard Care Can Do

Depending on your situation, your cardiologist may use:

- **Guideline-directed medicines**, often a beta blocker, an ACE inhibitor, ARB or ARNI, spironolactone or a similar drug, and an SGLT2 inhibitor. In large trials, these lowered the risk of hospitalization and death.
- **Diuretics** (“water pills”) and, for some patients, **devices** such as a defibrillator (ICD)
- **Treating the cause**, cardiac rehab and, in advanced cases, evaluation for a heart pump (LVAD) or transplant

These treatments are backed by large trials. Stem cell therapy is not a replacement for any of them.

**Sudden chest pain, severe shortness of breath, fainting or rapid weight gain from fluid are emergencies.** Call emergency services. Don’t wait for a clinic appointment or travel.

## How MSCs Are Thought to Work in the Heart

MSCs are best understood as signaling cells. They release proteins and tiny vesicles that may calm inflammation and influence scarring. Very few cells stay in the heart, and they don’t become working heart muscle in meaningful numbers. When cells are given by IV, as in our protocol, many are first filtered through the lungs, so any heart benefit is thought to come mostly from body-wide effects on inflammation. Our guide to [what stem cells are](https://dreambody.clinic/what-are-stem-cells-plain-language-guide/) covers the basics.

## What the Research Shows

Most MSC trials in heart failure were small, and many injected cells directly into the heart muscle by catheter, a different route from an IV.

### IV trials (closest to our approach)

- **RIMECARD (Bartolucci et al., *Circulation Research*, 2017; 30 patients):** Adults with stable HFrEF on optimal medicines were randomly assigned to one IV infusion of donor umbilical cord MSCs (1 million cells per kilogram of body weight) or placebo. No infusion-related adverse events were reported. EF improved in the MSC group over 12 months, by about 7 percentage points vs about 2 with placebo. Symptom class and quality-of-life scores also improved in the MSC group. Deaths and hospital admissions didn’t differ.
- **Butler et al., 2017 (*Circulation Research*; 22 patients):** In non-ischemic cardiomyopathy (EF 40% or less), an IV of donor bone marrow MSCs (1.5 million per kilogram) **didn’t change EF or heart size** compared with placebo. Six-minute walk distance improved by about 36 meters, and a heart-failure quality-of-life score improved.

### Trials that injected cells into the heart

- **DREAM-HF (Perin et al., *Journal of the American College of Cardiology*, 2023; 565 patients):** The largest trial of its kind. Patients with HFrEF received 150 million donor bone marrow precursor cells injected into the heart muscle, or a sham procedure. **The trial missed its main goal:** the cells didn’t reduce repeat heart failure hospitalizations, and its secondary goals, including death from any cause, were also negative. In additional analyses, heart attacks and strokes were less common in the cell group, and EF rose modestly over 12 months, especially in people with higher inflammation markers. The authors called these signals worth testing further, not proof of benefit.
- **SCIENCE (Qayyum et al., *European Journal of Heart Failure*, 2023; 133 patients):** Donor fat-derived MSCs injected into the heart in ischemic HFrEF were safe over 3 years, but **showed no improvement over placebo** in heart size, EF, walking distance or quality of life.
- **CONCERT-HF (Bolli et al., *European Journal of Heart Failure*, 2021; 125 patients):** Patients’ own bone marrow MSCs injected into the heart improved quality-of-life scores, but **didn’t change EF, heart size, scar size or exercise capacity**, and didn’t significantly reduce cardiac events compared with placebo.
- **MSC-HF (Mathiasen et al., *European Heart Journal*, 2015; 60 patients):** Patients’ own MSCs injected into the heart improved heart size and EF compared with placebo, but symptoms and walking distance didn’t change.

### What the reviews say

A 2024 meta-analysis (Kavousi et al., *Journal of Translational Medicine*) pooled 17 randomized trials with 1,684 patients. It found MSCs were associated with lower death and rehospitalization rates and an average EF gain of about 3.4 percentage points. But the trials differed widely in cell type, dose and delivery (mostly injections into the heart or coronary arteries), and studies using fewer than 100 million cells did better on some outcomes.

**In plain language:** MSC treatments have generally been well tolerated in heart failure trials, and several small studies reported modest gains in EF, symptoms or quality of life. But the largest trial missed its main goal, other well-run trials found no benefit, and no trial has shown that MSCs replace any standard heart failure treatment. No MSC therapy is approved by the U.S. FDA for heart failure.

### How our protocol compares

The IV trial closest to ours (RIMECARD) used umbilical cord MSCs at 1 million cells per kilogram, roughly 70 to 100 million cells for most adults. Ours is a single IV infusion of 300 million cells from Wharton’s jelly (umbilical cord tissue) and placenta, about three times higher. No published trial has tested our exact dose and cell source in heart failure, and higher doses haven’t been shown to work better by IV. You should know that before deciding.

## Our Heart Failure Protocol

Here’s exactly what we offer, as listed on our [congestive heart failure treatment page](https://dreambody.clinic/congestive-heart-failure-stem-cell-treatment/). The same package is offered for [recovery after a heart attack](https://dreambody.clinic/post-heart-attack-stem-cell-treatment/).

- **Cardiac testing first:** EKG, echocardiogram, chest X-ray and bloodwork, reviewed by our internist and cardiologist. They can decline treatment if they believe your heart isn’t ready for it.
- **300 million MSCs by IV infusion.** Donor (allogeneic) cells from Wharton’s jelly and placenta from healthy, live births, expanded in GMP-grade, xeno-free medium in the cleanroom of our on-site lab, which holds three COFEPRIS licenses. Cells are tested by third-party, COFEPRIS-authorized labs. They come out of culture the day before treatment and are given within 24 hours.
- **NAD+ and high-dose vitamin C IV drip**, given after the cells. Our physicians review whether it’s right for your heart and kidneys.
- **Price:** $11,800 USD, all-inclusive for the items above.

See our [Certified Stem Cells page](https://dreambody.clinic/certified-stem-cells/) and our guide to [how our cells are made](https://dreambody.clinic/science-and-quality-of-our-mesenchymal-stem-cells/).

### Your 6-day stay

- **Day 1:** Arrive at Puerto Vallarta airport (PVR) and rest at your hotel in or near Bucerias, Nayarit (Puerto Vallarta Area).
- **Day 2:** Bloodwork, EKG, echocardiogram and chest X-ray.
- **Day 3:** Our internist reviews your results and clears you, or not, for treatment. Payment is completed at the clinic.
- **Day 4:** Your cells are taken out of culture.
- **Day 5:** Stem cell IV, followed by the IV drip.
- **Day 6:** Fly home. We recommend one extra rest day if you can.

After you return home, we follow up remotely at 3, 6 and 12 months. Many patients report changes over 3 to 6 months, but results vary and some see little or no benefit. With heart failure, your cardiologist’s follow-up echocardiograms and lab tests are the best guide, so keep those appointments. See our [travel guide](https://dreambody.clinic/travel-guide-stem-cell-treatment-bucerias/) and [hotel options](https://dreambody.clinic/hotels/).

## Who May Be a Candidate

Every case is reviewed individually by our physicians. You may be a reasonable candidate to discuss MSC therapy with us if you:

- Have a confirmed diagnosis and recent records (echocardiogram, medication list, cardiology notes)
- Are stable on your current medicines, with no recent hospital stay for heart failure
- Have a cardiologist at home who will keep managing your care
- Are cleared by your cardiologist to fly and to stay at least six days
- Understand that results vary and improvement isn’t guaranteed

Our physicians may advise against treatment, or advise waiting, if you have:

- **An ejection fraction below 30%.** We don’t recommend flying to us by airplane at that level because of the risk of heart and blood pressure problems during flight.
- **Cancer within the past five years** (we don’t treat these patients)
- **Unstable symptoms** (a recent heart attack or hospital stay, chest pain at rest, uncontrolled rhythm problems, fluid overload) or **advanced kidney disease**

**About your medicines:** Don’t stop, skip or change any heart medicine because you’re considering stem cell therapy. Stopping heart failure medicines, diuretics or blood thinners on your own can be dangerous. Any change should be decided by your cardiologist. Tell us about every medicine and device you have.

## Risks and Side Effects

MSC treatments have generally been well tolerated in heart failure trials, but long-term data are limited.

- **Fever or headache:** about 1 in 100 of our patients have a mild fever and/or headache for a few hours after treatment or the next day.
- **IV risks:** any IV carries a small risk of infection, bruising or vein irritation. Rarely, it can release a blood clot, a risk that is higher with high cholesterol. Our pre-treatment bloodwork is part of how we screen for this.
- **Heart-specific concerns:** blood pressure can rise after treatment, and people with heart failure may have extra fluid around the heart. That’s why we require cardiac testing and clearance first.
- **Travel:** a long trip can strain a weak heart. Plan it with your cardiologist.

The biggest risk is delaying proven care in the hope that stem cells will be enough. Please don’t. Our [safety and side effects guide](https://dreambody.clinic/stem-cell-therapy-safety-side-effects-results/) has more detail.

## Questions to Ask Any Clinic

Wherever you go, ask which trials (including negative ones) support the protocol, why the dose was chosen, what heart tests come first, and how the clinic works with your cardiologist. See our guide to [choosing a stem cell clinic](https://dreambody.clinic/how-to-choose-a-stem-cell-clinic/). If you’re researching for a parent, see [Helping a Parent Decide](https://dreambody.clinic/helping-a-parent-decide-stem-cell-therapy/).

## Frequently Asked Questions

**Can stem cells make my heart normal again?** No study has shown that. Some small trials reported modest EF gains of a few percentage points, while others, including large ones, found no difference from placebo. Scar from a heart attack doesn’t turn back into working muscle.

**Will my ejection fraction go up?** It might not. In RIMECARD, the average gain was about 7 points over a year; in other trials there was no change. Your cardiologist’s echocardiogram is the way to check.

**Can this help me avoid a heart pump or transplant?** No study has shown that MSCs prevent or delay an LVAD or transplant. If your doctors recommend an evaluation, please take that advice seriously.

**Will insurance cover it?** Generally not. Many U.S. insurers classify it as experimental. See our guide to [stem cell therapy costs in Mexico](https://dreambody.clinic/stem-cell-therapy-cost-mexico/).

## Thinking About Your Options?

If you’re wondering whether MSC therapy is worth exploring alongside your heart care, a free consultation is a good place to start. It’s a conversation, not a commitment. A physician will review your echocardiogram and medicines, explain what the research does and doesn’t show, and tell you honestly whether this may make sense for you.

**[Schedule your free consultation](https://dreambody.clinic/contact/)**, call (888) 704-3977, WhatsApp +52 322 232 1055, or email info@dreambodyclinic.net.

---

*Disclaimer: This article is for educational purposes and is not medical advice. Mesenchymal stem cell therapy for heart failure is investigational and is not approved by the U.S. FDA. Published human evidence is limited and mixed, results vary, and some patients see little or no benefit. Stem cell therapy offers no guarantees and does not replace heart failure medicines, devices, surgery, transplantation or your cardiologist’s care. Do not stop or change any medication without talking to your own doctor. Treatment eligibility is decided only after a review of your medical history. Dream Body Clinic is located in Bucerias, Nayarit (Puerto Vallarta Area), Mexico, and operates under the oversight of COFEPRIS, Mexico’s health regulator.*
